Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Ovarian Neoplasms

  Free Subscription


Articles published in Obstet Gynecol

Retrieve available abstracts of 34 articles:
HTML format
Text format



Single Articles


    February 2017
  1. GOCKLEY A, Melamed A, Bregar AJ, Clemmer JT, et al
    Outcomes of Women With High-Grade and Low-Grade Advanced-Stage Serous Epithelial Ovarian Cancer.
    Obstet Gynecol. 2017 Feb 6. doi: 10.1097/AOG.0000000000001867.
    PubMed     Text format     Abstract available


    May 2016
  2. WRIGHT JD, Hou JY, Burke WM, Tergas AI, et al
    Utilization and Toxicity of Alternative Delivery Methods of Adjuvant Chemotherapy for Ovarian Cancer.
    Obstet Gynecol. 2016.
    PubMed     Text format     Abstract available


  3. CHATTERJEE S, Chen L, Tergas AI, Burke WM, et al
    Utilization and Outcomes of Chemotherapy in Women With Intermediate-Risk, Early-Stage Ovarian Cancer.
    Obstet Gynecol. 2016.
    PubMed     Text format     Abstract available


  4. MOTOHARA T, Fujimoto K, Tayama S, Narantuya D, et al
    CD44 Variant 6 as a Predictive Biomarker for Distant Metastasis in Patients With Epithelial Ovarian Cancer.
    Obstet Gynecol. 2016.
    PubMed     Text format     Abstract available


  5. HARMSEN MG, IntHout J, Arts-de Jong M, Hoogerbrugge N, et al
    Salpingectomy With Delayed Oophorectomy in BRCA1/2 Mutation Carriers: Estimating Ovarian Cancer Risk.
    Obstet Gynecol. 2016.
    PubMed     Text format     Abstract available


  6. CHAPPELL NP, Miller C, Barnett J, Fielden A, et al
    Is FDA Approved Bevacizumab Cost-Effective in the Setting of Platinum-Resistant Recurrent Ovarian Cancer? [18].
    Obstet Gynecol. 2016;127 Suppl 1:6S-7S.
    PubMed     Text format     Abstract available


  7. GOTIMER KF, Bondoc C, Chalas E, Villella JA, et al
    Self Reported Quality of Life Among Patients Who Have Undergone Outpatient IP Chemotherapy for Ovarian Cancer [11].
    Obstet Gynecol. 2016;127 Suppl 1:4S.
    PubMed     Text format     Abstract available


    April 2016
  8. POWER L, Lefas G, Lambert P, Kim D, et al
    Hormone Use After Nonserous Epithelial Ovarian Cancer: Overall and Disease-Free Survival.
    Obstet Gynecol. 2016.
    PubMed     Text format     Abstract available


    March 2016
  9. SCHORGE JO
    What Is New in Prevention of Ovarian Cancer?: Best Articles From the Past Year.
    Obstet Gynecol. 2016.
    PubMed     Text format     Abstract available


    February 2016
  10. WRIGHT JD, Tergas AI, Hou JY, Burke WM, et al
    Trends in Periodic Surveillance Testing for Early-Stage Uterine Cancer Survivors.
    Obstet Gynecol. 2016.
    PubMed     Text format     Abstract available


    December 2015
  11. LIN JJ, Egorova N, Franco R, Prasad-Hayes M, et al
    Ovarian Cancer Treatment and Survival Trends Among Women Older Than 65 Years of Age in the United States, 1995-2008.
    Obstet Gynecol. 2015.
    PubMed     Text format     Abstract available


  12. WRIGHT JD, Huang Y, Burke WM, Tergas AI, et al
    Influence of Lymphadenectomy on Survival for Early-Stage Endometrial Cancer.
    Obstet Gynecol. 2015.
    PubMed     Text format     Abstract available


  13. WRIGHT JD, Jorge S, Tergas AI, Hou JY, et al
    Utilization and Outcomes of Ovarian Conservation in Premenopausal Women With Endometrial Cancer.
    Obstet Gynecol. 2015.
    PubMed     Text format     Abstract available


    November 2015
  14. BARBER EL, Boggess JF, Van Le L, Kim KH, et al
    Association of Preoperative Thrombocytosis and Leukocytosis With Postoperative Morbidity and Mortality Among Patients With Ovarian Cancer.
    Obstet Gynecol. 2015.
    PubMed     Text format     Abstract available


    October 2015
  15. ESSELEN KM, Vitonis A, Einarsson J, Muto MG, et al
    Health Care Disparities in Hysterectomy for Gynecologic Cancers: Data From the 2012 National Inpatient Sample.
    Obstet Gynecol. 2015.
    PubMed     Text format     Abstract available


  16. TEMKIN SM, Terplan M
    Trends in Relative Survival for Ovarian Cancer From 1975-2011.
    Obstet Gynecol. 2015;126:898.
    PubMed     Text format    


  17. WRIGHT JD, Chen L, Hershman DL
    In Reply.
    Obstet Gynecol. 2015;126:898-9.
    PubMed     Text format    


    September 2015
  18. MELAMED A, Rauh-Hain JA, Clemmer JT, Diver EJ, et al
    Changing Trends in Lymphadenectomy for Endometrioid Adenocarcinoma of the Endometrium.
    Obstet Gynecol. 2015.
    PubMed     Text format     Abstract available


    July 2015
  19. CRESS RD, Chen YS, Morris CR, Petersen M, et al
    Characteristics of Long-Term Survivors of Epithelial Ovarian Cancer.
    Obstet Gynecol. 2015.
    PubMed     Text format     Abstract available


  20. PRAT J
    Staging Classification for Cancer of the Ovary, Fallopian Tube, and Peritoneum: Abridged Republication of Guidelines From the International Federation of Gynecology and Obstetrics (FIGO).
    Obstet Gynecol. 2015;126:171-4.
    PubMed     Text format    


    June 2015
  21. WRIGHT JD, Chen L, Tergas AI, Patankar S, et al
    Trends in relative survival for ovarian cancer from 1975 to 2011.
    Obstet Gynecol. 2015;125:1345-52.
    PubMed     Text format     Abstract available


  22. RAUH-HAIN JA, Hariton E, Clemmer J, Clark RM, et al
    Incidence and effects on mortality of venous thromboembolism in elderly women with endometrial cancer.
    Obstet Gynecol. 2015;125:1362-70.
    PubMed     Text format     Abstract available


    April 2015
  23. YEH KE, Marcus PS, Fong TL
    Paraneoplastic Cholestasis Associated With Ovarian Dysgerminoma.
    Obstet Gynecol. 2015.
    PubMed     Text format     Abstract available


    March 2015
  24. BRISTOW RE, Chang J, Ziogas A, Campos B, et al
    Sociodemographic Disparities in Advanced Ovarian Cancer Survival and Adherence to Treatment Guidelines.
    Obstet Gynecol. 2015.
    PubMed     Text format     Abstract available


    January 2015
  25. SPENCER RJ, Hayes KD, Rose S, Zhao Q, et al
    Risk Factors for Early-Occurring and Late-Occurring Incisional Hernias After Primary Laparotomy for Ovarian Cancer.
    Obstet Gynecol. 2015.
    PubMed     Text format     Abstract available


  26. KWON JS, McAlpine JN, Hanley GE, Finlayson SJ, et al
    Costs and Benefits of Opportunistic Salpingectomy as an Ovarian Cancer Prevention Strategy.
    Obstet Gynecol. 2015.
    PubMed     Text format     Abstract available


  27. JANCO JM, Gloviczki P, Friese JL, Cliby WA, et al
    Lymphatic Mapping and Ligation for Persistent Ascites After Surgery for Gynecologic Malignancy.
    Obstet Gynecol. 2015.
    PubMed     Text format     Abstract available



  28. Committee opinion no. 620: salpingectomy for ovarian cancer prevention.
    Obstet Gynecol. 2015;125:279-81.
    PubMed     Text format     Abstract available


  29. WIN AK, Reece JC, Ryan S
    Family History and Risk of Endometrial Cancer: A Systematic Review and Meta-analysis.
    Obstet Gynecol. 2015;125:89-98.
    PubMed     Text format     Abstract available


    November 2014
  30. ERICKSON BK, Kinde I, Dobbin ZC, Wang Y, et al
    Detection of Somatic TP53 Mutations in Tampons of Patients With High-Grade Serous Ovarian Cancer.
    Obstet Gynecol. 2014;124:881-5.
    PubMed     Text format     Abstract available


  31. MUTCH DG
    Can molecular diagnostics usher in a new era for screening, diagnosis, and treatment of ovarian cancer?
    Obstet Gynecol. 2014;124:870-2.
    PubMed     Text format    


  32. CREININ MD, Zite N
    In reply.
    Obstet Gynecol. 2014;124:1033-4.
    PubMed     Text format    


  33. HSIEH G, Anderson ML
    Female tubal sterilization: the time has come to routinely consider removal.
    Obstet Gynecol. 2014;124:1033.
    PubMed     Text format    


    September 2014
  34. CREININ MD, Zite N
    Female tubal sterilization: the time has come to routinely consider removal.
    Obstet Gynecol. 2014;124:596-9.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Ovarian Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: